SAB Biotherapeutics (SABS) Depreciation & Amortization (CF) (2021 - 2026)

SAB Biotherapeutics (SABS) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $700000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 12.5% year-over-year to $700000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (down 15.8% YoY) and the FY2025 annual result came in at $3.0 million, down 36.17% from the prior year.
• Depreciation & Amortization (CF) retreated to $700000.0 in Q1 2026, from $746830.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.0 million in Q1 2024 to a low of $636000.0 in Q1 2022.
• A 5-year average of $904899.9 and a median of $890000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) jumped 189.7% — and 2025, when it plunged 59.25%.
• Tracing SABS's Depreciation & Amortization (CF) over 5 years: stood at $899429.0 in 2022, then rose by 11.18% to $1.0 million in 2023, then slipped by 20.0% to $800000.0 in 2024, then retreated by 6.65% to $746830.0 in 2025, then decreased by 6.27% to $700000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $700000.0 (Q1 2026), $746830.0 (Q4 2025), and $700000.0 (Q3 2025), per Business Quant data.